MedTrace Logo

Tolerability of Grazax in Patients With Hayfever in Real Life Settings

NCT01433510 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 628

Last updated 2024-05-29

No results posted yet for this study

Summary

The purpose of this study is to assess the safety profile of specific immunotherapy with Grazax for three consecutive grass pollen seasons.

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

DRUG

Grazax

1 tablet/day - pre and co-seasonal

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • François FW Wessel, MD · Centre Hospitalier Universitaire F-44000 Nantes

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-10-31
Completion
2010-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01433510 on ClinicalTrials.gov